Home » News » Drug Sponsors » Pfizer files NDA for new oncology drug

Pfizer files NDA for new oncology drug

Wednesday, May 18, 2011

Pfizer has filed a new drug application for its oncology drug crizotinib with regulators in the U.S. and Japan.

Crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, has been accepted for filing and granted priority review status by the FDA. It has also been submitted to the Japanese Ministry of Health, Labour and Welfare for the treatment of patients with ALK-positive advanced non-small cell lung cancer (NSCLC).

Results from an expansion cohort of a phase I/II trial showed that at eight weeks, 87% of patients given crizotinib had responded to treatment—57% of those experiencing tumor shrinkage. About 3%-5% of NSCLC patients have tumors that are positive for the ALK- fusion gene.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!